-
Posted by
Two Blokes May 24, 2025 -
Filed in
Stock
-
8 views
NovoCure's Q1 earnings beat and strong commercial momentum, especially with Optune Lua in NSCLC, signal renewed growth potential and investor optimism. Key catalysts ahead include the PANOVA-3 data at ASCO, PMA submissions, and possible NCCN guideline inclusion, all of which could drive adoption and revenue. International expansion, particularly in Europe and Japan, is accelerating, with robust demand and a solid cash position supporting pipeline and scaling efforts.
